Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

537
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
537
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

524
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
524
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

559
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
559
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

588
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
588
Combining Functions01:16

Combining Functions

252
Functions can be combined to form new mathematical models that describe interactions between variables. These combinations are fundamental in understanding relationships between changing quantities and are commonly encountered in scientific and engineering contexts. The combination methods—addition, subtraction, multiplication, division, and composition—each have unique implications for the resulting function’s domain and behavior.When combining functions through arithmetic...
252
Impedance Combination01:21

Impedance Combination

759
Consider a string of christmas lights, each bulb symbolizing an impedance element. In this series configuration, the flow of electric current remains uniform across every component. This behavior aligns with Kirchhoff's Voltage Law (KVL), which asserts that the total impedance in such a setup equals the sum of individual impedances—akin to resistors in series. It follows that the voltage from the power source is distributed proportionally among these components, adhering to the voltage...
759

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results.

Journal of Crohn's & colitis·2026
Same author

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

A metabolic constraint in de novo NAD+ synthesis drives mucosal inflammation in IBD.

Journal of Crohn's & colitis·2026
Same author

Hyperbaric oxygen therapy alters bowel perfusion and improves outcomes in patients with treatment-refractory ulcerative colitis: a prospective pilot trial.

Journal of Crohn's & colitis·2026
Same author

Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis.

United European gastroenterology journal·2026
Same author

Faecalibacterium prausnitzii EXL01 for the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Crohn's Disease: a first in human trial.

Nature communications·2026

Related Experiment Video

Updated: Feb 14, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K

Combination Immunosuppression in IBD.

Steven Bots1, Krisztina Gecse1, Murray Barclay2

  • 1Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands.

Inflammatory Bowel Diseases
|February 21, 2018
PubMed
Summary
This summary is machine-generated.

Combination therapy with biologics and immunosuppressives may benefit inflammatory bowel disease (IBD) patients, especially with infliximab. Lowering immunosuppressive doses or limiting treatment duration can mitigate risks like infections and immunogenicity.

More Related Videos

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

10.6K
Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

69.0K

Related Experiment Videos

Last Updated: Feb 14, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K
Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

10.6K
Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

69.0K

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • The optimal use of biologic agents in inflammatory bowel disease (IBD) remains debated, specifically regarding monotherapy versus combination therapy with immunosuppressives.
  • While registration trials for TNF antagonists, vedolizumab, and ustekinumab did not demonstrate superiority of combination therapy, they were not powered to detect such differences.
  • Postmarketing data suggest combination therapy reduces immunogenicity, a common cause of infusion/injection reactions.

Purpose of the Study:

  • To evaluate the efficacy and safety of biologic monotherapy versus combination therapy with immunosuppressives in IBD.
  • To analyze the impact of combination therapy on immunogenicity and toxicity in IBD patients treated with biologics.
  • To provide guidance on the current use of combination therapy in IBD management.

Main Methods:

  • Review of registration trials for biologics in Crohn's disease and ulcerative colitis.
  • Analysis of postmarketing studies and real-world data on biologic therapy in IBD.
  • Examination of specific trial data, such as SONIC and UC-SUCCESS, for infliximab combination therapy.

Main Results:

  • Combination azathioprine-infliximab demonstrated superiority in Crohn's disease and ulcerative colitis in specific trials (SONIC, UC-SUCCESS).
  • Combination therapy with TNF antagonists is linked to increased toxicity, including infections and lymphoproliferative disease.
  • Lowering immunosuppressive doses or using combination therapy for a limited duration (e.g., 12 months) may reduce toxicity while maintaining efficacy and lowering immunogenicity.

Conclusions:

  • Combination treatment with infliximab, particularly in the initial 12 months, shows clear benefits for IBD patients.
  • For other biologics like vedolizumab and ustekinumab, current data do not provide definitive guidance on combination therapy.
  • In patients without increased toxicity risk or with limited options, initiating combination therapy with any biologic during the initiation phase may be a prudent strategy.